Past Seminars
This is an accordion element with a series of buttons that open and close related content panels.
June 2023 - Pallavi Tiwari
In this talk, Dr. Tiwari will focus on her lab’s recent efforts in developing machine learning techniques to capture insights into the underlying tumor biology as observed across non-invasive imaging, histopathology, and omics data. She will focus on applications of this work for predicting disease outcome, recurrence, progression and response to therapy specifically in the context of brain tumors. She will also discuss current efforts in developing new image-based features for post-treatment evaluation and predicting response to chemo-radiation treatment. Dr. Tiwari will conclude her talk with a discussion of some of the translational aspects of her work from a clinical perspective.
May 2023 - Emery Bresnick
The Bresnick group conducts basic and translational research on genomics/epigenomics and normal and malignant hematopoiesis. They have discovered GATA2 enhancers and mechanisms that are essential for hematopoiesis and embryonic development, and their disruption generates a predisposition to develop myelodysplastic syndromes and acute myeloid leukemia. Studies on GATA2, DDX41 and other critical determinants of hematopoiesis have unveiled paradigms to explain hematopoietic stem cell generation, progenitor fate decisions, and erythrocyte development as well as clinical genetic diagnostic strategies.
“From Human Genetics to Stem Cell and Blood Cancer Mechanisms and Applications”
April 2023 - Jomol Mathew
After receiving a PhD from the University of Massachusetts Amherst and doing a post-doctoral fellowship at the NY University School of Medicine, Dr. Mathew’s research and academic service focus has been on development of technological devices, informatics platforms, data analytics and decision support for improving wellness, disease prevention, early diagnosis, and efficient disease management. She has also led development of phenotype registries with metadata and standard vocabulary from EHR data. Most recently she served as Chief Research Informatics Officer at the University of Massachusetts Medical School. Dr. Mathew became associate dean for informatics and information technology for the School of Medicine and Public Health in October 2021.
March 2023 - Stephanie Savage
Dr. Savage is certified by the American Board of Surgery in General Surgery and Surgical Critical Care. Her clinical practice focuses on care of the acute injured patient, the management of emergent general surgical diseases and providing critical care in the Intensive Care Unit setting. Dr. Savage is nationally recognized and serves on multiple committees for the American Association for the Surgery of Trauma, the Western Trauma Association, the Eastern Association for the Surgery of Trauma and the American Board of Surgery. Dr. Savage’s research interests focus on massive hemorrhage and the interaction between abnormal clot formation and inflammation following injury. Dr. Savage is also well-published in research surrounding Emergency General Surgery grading systems and management.
“Interplay of Coagulation and Inflammation following Major Injury”
February 2023 - Lixin Rui
Dr. Lixin Rui is a faculty member in the Division of Hematology, Medical Oncology and Palliative Care within the Department of Medicine. He is a lecturer and trainer in several University of Wisconsin School of Medicine and Public Health basic science courses and graduate programs. A former UW Institute for Clinical and Translational Research (ICTR) KL2 scholar, Dr. Rui has an active lymphoma biology research program. He is a member of the American Society of Hematology and the American Association for Cancer Research.
Dr. Rui’s research focuses on lymphoma biology, with an emphasis on JAK-STAT signaling in lymphomagenesis. Deregulation of this pathway contributes to pathogenesis of Hodgkin lymphoma and Non-Hodgkin lymphoma, including aggressive diffuse large B-cell lymphoma. Dr. Rui’s research aims to identify JAK and its downstream molecular targets for therapeutic applications to these cancers. His research interests also include investigation of the F-box protein FBXO10, which he has recently characterized as a potential tumor suppressor.
December 2022 - Kaitlyn Kelly
Dr. Kelly’s primary clinical practice includes the treatment of upper gastrointestinal malignancies, including gastric, pancreatic, and hepatobiliary cancers, as well as peritoneal surface malignancy, melanoma, and sarcoma. She is particularly interested in developing minimally invasive techniques for cancer surgery. Dr. Kelly’s primary clinical and research interest is gastric cancer. She is among the highest-volume gastric cancer surgeons in the country with over 10 year of experience, and has pioneered minimally-invasive surgical techniques for gastrectomy with comprehensive lymph node removal. Dr. Kelly also performs some operations with an open technique when necessary, and can perform additional procedures to treat liver cysts, chronic pancreatitis, and gallbladder disease. Dr. Kelly is board-certified in Complex General Surgical Oncology and General Surgery.
November 2022 - Qiongshi Lu
Dr. Lu received his Bachelor’s at Tsinghua University (Mathematics, 2012) and Ph.D. at Yale University (Biostatistics, 2017). He is currently an Assistant Professor in the Department of Biostatistics and Medical Informatics at UW-Madison. The Lu Lab develops and employs statistical methods to identify and interpret genetic associations for human complex traits. In particular, areas of expertise in the Lu Lab include genome-wide association study, non-coding genome annotation, genetic correlation estimation, polygenic risk prediction, and gene-environment interaction.
“Optimizing and benchmarking polygenic risk score with GWAS summary data”
September 2022 - Jessica Lang
Jessica obtained her bachelors (Genetics, 2009) and doctorate (Cancer Biology, 2014) at the University of Wisconsin-Madison. She then completed two postdoctoral fellowships at Arizona State University and The Translational Genomics Research Institute (TGen). Jessica was awarded an NCI K99/R00 in 2019 to focus her studies on the role of super-enhancers in high-grade serous ovarian carcinomas. She joined the University of Wisconsin-Madison faculty in 2021, where she will leverage her experience in translational biology, genomics, and epigenetics.
The Lang Lab employs genomics technologies and translational models to determine the role of somatic mutation to epigenetic modifiers in the development and therapeutic vulnerabilities of ovarian cancers.
“Therapeutic vulnerabilities in ovarian cancers and implications of platinum treatment”